New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Century Therapeutics, Inc. (IPSC) vs Scribe Therapeutics Inc. (SCTX)

Century Therapeutics, Inc. and Scribe Therapeutics Inc. are both Biotechnology companies. Century Therapeutics, Inc. and Scribe Therapeutics Inc. are of similar size ($250.4M and $239.7M). Across the 5 metrics below, Century Therapeutics, Inc. leads on 4 and Scribe Therapeutics Inc. on 1.

Valuation

Metric IPSC SCTX Biotechnology median
P/E n/m n/m 8.49
P/S 2.10 6.75 8.56
P/B 1.15 1.40 2.04
Price to free cash flow n/m — 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 1.08 0.02 8.00
Earnings yield (55.01%) (80.87%) (35.81%)
Free cash flow yield (35.20%) — (25.41%)

Profitability

Metric IPSC SCTX Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (28.42%) — 0.00%
Net margin (19.10%) — 0.00%
Free cash flow margin (99.74%) — 0.00%
Return on equity (51.16%) — (51.58%)
Return on assets (38.96%) — (45.91%)
Return on invested capital (71.47%) — 0.00%

Growth

Metric IPSC SCTX Biotechnology median
Revenue growth (TTM) 8,286.72% — 7.20%
EPS growth (last fiscal year) 91.30% — 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric IPSC SCTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.74 4.72 4.79
Net debt to EBITDA 17.95 — 1.01

Dividend

Metric IPSC SCTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IPSC SCTX Biotechnology median
Market cap 239.71m 250.35m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack